Expert Cancer Panel: Newly diagnosed CD30 negative peripheral T-cell lymphoma and HLH

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Recorded on 10/9/2021

60-year-old female presents with newly diagnosed CD30- peripheral T cell lymphoma and HLH.

Summary:
- For a patient with newly diagnosed CD30- peripheral T cell lymphoma and secondary HLH, the preferred treatment regimen would be CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone
- Given this patient's multiple medical comorbidities including Takotsubo cardiomyopathy, COVID-19, and recent gastrointestinal bleeding, the panel recommends avoiding full dose chemotherapy and adhering to the HLH-94 protocol which involves etoposide and dexamethasone. If full dose chemotherapy is chosen, they recommend CEOP (cyclophosphamide, etoposide, vincristine, prednisone), sparing the doxorubicin which can contribute to more myelosuppression and cardiac toxicity.


At PrecisCa, we are dedicated to providing expert second opinions for cancer patients to ensure they receive the best possible care. Our videos cover a wide range of topics related to oncology, including in-depth discussions on different types of cancer, treatment options, patient stories, and the latest advancements in cancer research. Whether you're a patient, caregiver, or simply seeking to expand your knowledge, our goal is to support you on your healthcare journey.

Visit our website: https://www.PrecisCa.com for more detailed information and personalized second opinions.

Stay connected with us:
Facebook: / precisca.oncology
Twitter: https://twitter.com/precisca_?lang=en
-Instagram: / precisca_oncology
-LinkedIn: / precisca

Don't forget to subscribe to our channel for regular updates and new videos. Hit the bell icon to receive notifications every time we upload. #Oncology #CancerCare #CancerSupport #CancerResearch #Health #Healthcare #CancerTreatment #CancerAwareness #PatientCare #MedicalAdvice #PrecisCa
Category
Oncology
Be the first to comment

Up Next